Ibuprofen B. Braun (Ibuprofen)

Ibuprofen works by reversibly inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the synthesis of prostaglandins—molecules that mediate pain, fever, and inflammation—thereby providing analgesic, antipyretic, and anti‑inflammatory effects.

The specific dose and infusion rate of Ibuprofen B. Braun are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and therapeutic goals. Only a qualified healthcare professional should set the dosing regimen.

The safety of intravenous ibuprofen in pregnancy has not been established, and it is generally avoided unless the potential benefit justifies the risk. Limited data exist for breastfeeding; clinicians should assess risks and consider alternative therapies when possible.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with other injectable NSAIDs such as ketorolac, ibuprofen offers a similar mechanism of COX inhibition but may have a slightly longer half‑life and a different safety profile, particularly regarding renal and gastrointestinal effects. Choice of agent depends on clinical judgment, patient comorbidities, and institutional protocols.

Ibuprofen B. Braun should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before administration, inspect the solution for particulate matter or discoloration and use aseptic technique as per hospital pharmacy standards.

The product is supplied as a sterile intravenous solution and is administered by slow infusion through a dedicated IV line under the supervision of qualified medical personnel. The infusion rate and total volume are set by the prescriber according to the clinical situation.

Serious risks include gastrointestinal bleeding, severe allergic reactions such as anaphylaxis, acute renal failure, hepatic injury, and thrombotic cardiovascular events. Patients should be monitored closely for signs of bleeding, renal dysfunction, or hypersensitivity during therapy.

Ibuprofen B. Braun is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal ulceration or bleeding, severe uncontrolled heart failure, and in those receiving certain anticoagulants where bleeding risk is unacceptable. Clinicians must evaluate individual contraindications before prescribing.